Abstract
The differences in the clinical course and histopathology of sporadic and neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNST) were investigated retrospectively. The collective comprised 38 NF1 patients and 14 sporadic patients. NF1 patients were significantly younger at diagnosis (p < 0.001) and had a significantly shorter survival time than sporadic patients (median survival 17 months vs. 42 months, Breslow p < 0.05). The time interval to local recurrence and metastatic spread was also significantly shorter in NF1 patients (9.4 months vs. 30.0 months, p < 0.01; 9.1 months vs. 33.2 months, p < 0.001, respectively). In patients with the original histopathological data available (22 NF1 patients, 14 sporadic cases), NF1-associated MPNST showed a significantly higher cellularity compared to sporadic tumors (p < 0.001) whereas sporadic MPNST featured a significantly higher pleomorphism (p< 0.01). Most importantly, while histopathological variables correlated with French Fédération Nationale des Centres de Lutte Contre le Cancer grading in sporadic MPNST, this was not the case for NF1-associated tumors. The differences between NF1-associated and sporadic MPNST in regard to the clinical course and histopathology may reflect some fundamental differences in biology and pathomechanism of the two tumor groups. Our findings indicate the necessity for a separate grading scheme which takes into account the genetic background in NF1 patients.
Similar content being viewed by others
References
Perrin RG, Guha A (2004) Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am 15:203–216
Ducatman BS, Scheithauer BW, Piepgras DG et al (1986) Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 57:2006–2021
Hruban RH, Shiu MH, Senie RT et al (1990) Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer 66:1253–1265
Evans DG, Baser ME, McGaughran J et al (2002) Malignant peripheral nerve sheath tumors in neurofibromatosis 1. J Med Genet 39:311–314
Kleihues P, Cavenee WK (eds) (2000) Pathology and genetics of tumors of the nervous system. International Agency for Research on Cancer, Lyon
Frahm S, Mautner VF, Brems H et al (1996) p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol 106:282–288
Perry A, Roth KA, Banerjee R et al (2001) NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 159:57–61
Fletcher DM, Unni KK, Mertens F (eds) (2002) Pathology and genetics of tumors of soft tissue and bone. International Agency for Research on Cancer, Lyon
Coindre JM, Trojani M, Contesso G et al (1986) Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer 58:306–309
Costa J, Wesley RA, Glatstein E et al (1984) The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer 53:530–541
Kourea HP, Cordon-Cardo C, Dudas M et al (1999) Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol 155:1885–1891
Leroy K, Dumas V, Martin-Garcia N et al (2001) Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol 137:908–913
Nielsen GP, Stemmer-Rachamimov AO, Ino Y et al (1999) Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am J Pathol 155:1879–1884
DeClue JE, Heffelfinger S, Benvenuto G et al (2000) Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 105:1233–1241
Watson MA, Perry A, Tihan T et al (2004) Gene expression profiling reveals unique molecular subtypes of neurofibromatosis type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol 14:297–303
Agesen TH, Florenes VA, Molenaar WM et al (2005) Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol 64:74–81
Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278:51–57
Stumpf DA, Alksne JF, Annegers JF (1988) Neurofibromatosis. NIH consensus development conference statement. Arch Neurol 45:575–578
Guillou L, Coindre JM, Bonichon F et al (1997) Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 15:350–362
Wong WW, Hirose T, Scheithauer BW et al (1998) Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys 42:351–360
Ramanathan RC, Thomas JM (1999) Malignant peripheral nerve sheath tumors associated with von Recklinghausen’s neurofibromatosis. Eur J Surg Oncol 25:190–193
Loree TR, North JH Jr, Werness BA et al (2000) Malignant peripheral nerve sheath tumors of the head and neck: analysis of prognostic factors. Otolaryngol Head Neck Surg 122:667–672
King AA, Debaun MR, Riccardi VM et al (2000) Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 93:388–392
Acknowledgement
This study was supported by ‘Hamburger Stiftung zur Foerderung der Krebsbekaempfung’ (No. 154) und ‘Deutsche Krebshilfe’ (70-3072).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hagel, C., Zils, U., Peiper, M. et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol 82, 187–192 (2007). https://doi.org/10.1007/s11060-006-9266-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-006-9266-2